The New Haven, Connecticut-based firm plans to market 13.4 million shares for between $14 to $16 each, according to its filing Wednesday with the US Securities and Exchange Commission. At the top of that range, Veradermics would have a market value of roughly $534 million based on the outstanding shares listed in its filing.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
